Further Information
Interleukin-33; IL-1F11; NF-HEV
ELISA: (direct or indirect: 1:2,000-1:5,000). Functional Application (Blocking). Immunohistochemistry (paraffin sections (1:50-1:200)). Western blot: (1:2,000-1:5,000 using ECL. Suggested blocking and dilution buffer is PBST with 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at rooom temperature). Optimal conditions should be determined individually for each application.
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.
Liquid. 0.2um-filtered solution in PBS, pH 7.4. Contains no preservatives.
1 mg/ml
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Recombinant human IL-33.
90865
interleukin 33
IL33
Homo sapiens
Liquid
15559209
NP_254274
Innate Immunity,Functional Assays
Recognizes human IL-33. Does not cross-react with mouse IL-33.
O95760
Optimal dilutions for each application to be determined by the researcher.
